Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Vowst Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The expansion observed during the historic period was driven by a rising number of recurrent C. diff infections, the shortcomings of conventional antibiotic treatments, proven effectiveness of microbiome-based therapies, increasing rates of infections acquired in hospitals, and more streamlined regulatory frameworks for live biotherapeutic products.
The expansion during the forecast period is driven by the growth of microbiome-based drug development, a heightened demand for managing infections without antibiotics, increased funding for gut health studies, a wider uptake of precision microbiome treatments, and progress in oral biologic delivery technologies. Key developments expected in this period encompass a greater integration of microbiota-focused therapies, more attention to restoring the gut microbiome through specialized treatments, broader utilization of oral live biotherapeutic products, an extension of strategies aimed at preventing infection recurrence, and a stronger focus on therapies used alongside antibiotics.
Download A Free Sample Report For Comprehensive Market Insights:
Vowst Market Growth Factors Supporting Long-Term Expansion
The growing frequency of Clostridioides difficile infections is anticipated to drive the expansion of the Vowst market in the coming period. Clostridioides difficile infections (CDIs) are diseases triggered by the bacterium Clostridioides difficile, commonly causing colon inflammation that manifests as severe diarrhea, abdominal discomfort, and fever. These infections are fueled by elements like extensive antibiotic use that disturbs gut microbiota, a higher occurrence of healthcare-associated infections, aging populations with compromised immune systems, and the emergence of hypervirulent C. difficile strains. Vowst addresses Clostridioides difficile infections (CDI) by reinstating the gut’s natural bacterial equilibrium, frequently upset by antibiotics. As an example, in March 2023, the National Library of Medicine (NLM), a US-based biomedical library, reported that Clostridioides difficile infection (CDI) affects approximately 500,000 people annually in the United States, with around 30,000 of those cases leading to death. Consequently, the rising prevalence of Clostridioides difficile infections is fueling the growth of the Vowst market.
Vowst Market Segment Landscape And Growth Potential
The vowst market covered in this report is segmented –
1) By Indication: Infectious Diseases, Gut Microbiota Restoration, Immune Modulation
2) By Distribution Channel: Hospitals, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Adult, Geriatric
Vowst Market Industry Trends Shaping Future Revenue Growth
A primary driver in the Vowst market involves the creation of novel products, including antibacterial approaches for recurrent clostridioides difficile infection (rCDI), in response to an increasing demand for more effective therapies that enhance patient recovery and lower the chances of infection returning. These antibacterial treatments for recurrent Clostridioides difficile infection signify targeted medical methods meant to locate and destroy C. difficile bacteria among individuals suffering from repeated infection episodes. As an example, in April 2023, Seres Therapeutics Inc., a biotechnology firm based in the United States, together with Nestlé Health Science, a pharmaceutical company from Switzerland, secured approval from the United States Food and Drug Administration (FDA) for Vowst (fecal microbiota spores, live-brpk). This orally administered microbiota-based therapy is intended to prevent the recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). Its design focuses on reestablishing a balanced gut microbiome, thereby minimizing the probability of further recurrences after the initial treatment.
Vowst Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the vowst market are Seres Therapeutics Inc.
Access The Complete Vowst Market Report:
Vowst Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the vowst market in 2025. The regions covered in the vowst market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model